Last week our CEO, Dikla Czaczkes Akselbrad, sat down with Ben Shamsian, CPA MBA at the Lytham Partners IR Spring 2026 Investor Conference to discuss recent development in the company. Here is a link to their conversation: https://bit.ly/43QZUB6
PolyPid Ltd.
Pharmaceutical Manufacturing
biopharma company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins
About us
We are a global clinical-stage bio-pharmaceutical company focused on developing, manufacturing and commercializing novel, locally administered therapies to improve surgical outcomes. Our PLEX (Polymer-Lipid Encapsulation matriX) technology is a unique platform that is anchored in the surgical site to provide controlled and continuous delivery of medications. Our product candidates are designed to deliver medications in the body over days to several months in a controlled manner. This allows surgeons to deliver medication right to the surgical site to improve patient outcomes in localized medical conditions such as; infection, pain, inflammation and cancer. Our initial infection treatment targets are Surgical Site Infections (SSIs), the second most prevalent type of Healthcare Acquired Infections (HAIs). SSIs have substantial negative impact on patients’ clinical outcomes and also pose a significant healthcare system burden. We strive to reduce overall surgical infection rates, including infections due to antibiotic-resistant bacteria which the FDA defined as being one of the world’s most pressing public health problems. NASDAQ: PYPD
- Website
-
http://www.polypid.com
External link for PolyPid Ltd.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Petah Tikva
- Type
- Public Company
Employees at PolyPid Ltd.
View 76 employees at PolyPid Ltd.
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Locations
-
Primary
Get directions
Ha'Sivim 18
Petah Tikva, IL
Updates
-
This afternoon we took a moment to celebrate an important milestone, the completion of our NDA submission. Behind this achievement is an incredible team effort, built on focus, collaboration, and persistence across the organization. We are proud of what we’ve accomplished together, and excited for what comes next 🚀 #LayerByLayer #RightWhereCareBegins
-
-
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀ Read the Full Press Release 👉 https://lnkd.in/etaMuK2h #PYPD #Nasdaq #News
-
-
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference Read the Full Press Release 👉 https://lnkd.in/eTt2WYFU #PYPD #Nasdaq #News
-
-
PolyPid Ltd. reposted this
A key limitation of conventional surgical antibiotic prophylaxis is delivering to the surgical site while maintaining therapeutic concentrations over extended periods of time. Dalit (Fellous) Hazan at PolyPid Ltd. discusses how locally administered, controlled-release delivery can extend coverage and reduce reliance on repeated dosing by maintaining higher concentrations at the surgical site, all while limiting systemic distribution. Get all of her insights on Drug Delivery Leader 🔽 https://lnkd.in/gFAd6DiM
-
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results Read the Full Press Release 👉 https://lnkd.in/dhKSgt5y #PYPD #Nasdaq #News
-
-
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026 Read the Full Press Release 👉 https://lnkd.in/dnqBp-kp #PYPD #Nasdaq #News
-
-
PolyPid Ltd. reposted this
Great discussion and lots of good insights on the potential use of DPLEX100 once it is approved at Surgical Infection Society annual meeting. #SISNA2026
-
-
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting Read the Full Press Release 👉 https://lnkd.in/dgkUG5AZ #PYPD #Nasdaq #News
-